The Latest research study released by Absolute Markets Insights Lumakras Drug Market with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth.Global Lumakras Drug Market is estimated to register a CAGR of XX% over the forecast period (2022 – 2030). Some of the Major Companies covered in this Research are: Amgen Inc., Boehringer Ingelheim, Eli Lilly and Company, Mirati Therapeutics Inc., Moderna Inc., Oblique Therapeutics AB, Revolution Medicines Inc., Silenseed LTD, Other Market Participants
Request a report sample to gain comprehensive insights @ https://www.absolutemarketsinsights.com/request_sample.php?id=1089
Global Lumakras Drug Market:
- By Therapy Type
- Monotherapy
- Combination Therapy
- By Disease Indication
- Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Purchase the latest in-depth Lumakras Drug Market report: https://www.absolutemarketsinsights.com/checkout?id=1089
Lumakras is a drug that is used to treat adults with non-small cell lung cancer (NSCLC) that has spread and has a mutation (change) in the KRAS gene. It's given to patients who have already had at least one other systemic treatment. According to the American Cancer Society, most lung cancer data include both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC accounts for about 13% of all lung cancers, while NSCLC accounts for 84%. Furthermore, the American Society of Clinical Oncology projected that 2.3 million people would be diagnosed with lung cancer worldwide in 2021. In the United States, an estimated 235,760 adults (119,100 men and 116,660 women) were diagnosed with the disease in the same year. Lung cancer is one of the most common cancer and the leading cause of cancer death. This disease is expected to cause deaths of 131,880 people (69,410 men and 62,470 women) in the United States in 2021.
Increasing pipeline medicines related to the lumakras drug is one of the significant factors expected to drive the growth of lumakras drug market over the forecast period. Rising incidence of various cancers, as well as growing popularity of advanced therapies, are fuelling the market growth. Major players are also contributing to market growth through developments. For instance, Mirati Therapeutics, Inc., a clinical-stage targeted oncology corporation, announced positive topline results from the potentially registration-allowing cohort of Phase 2 KRYSTAL-1 study, evaluating adagrasib in patients with advanced non-small-cell lung cancer (NSCLC) harboring the KRASG12C mutation consistent with previous systemic therapy, in September 2021. The company intends to publish detailed data from the KRYSTAL-1 study's continuing Phase 2 registration-enabling cohort in previously treated patients with KRASG12C-mutated NSCLC at a medical congress in early 2022.
SARS-CoV-2 (COVID-19) is one of the most serious public health emergencies the civilization has ever seen, with more than 770,000 deaths and immeasurable economic costs. COVID-19 was declared a global pandemic by the World Health Organization on March 12, 2020, as the epidemic condition worsened. In the first half of 2020, the impact of the COVID-19 pandemic on cancer care has led to decreases and delays in detecting new cancers and providing treatment. However, now that the covid-19 illnesses is being handled effectively by economies, key players and the government are focusing more proactively on other diseases, including cancer. The enhanced promise of innovation in cancer therapy showcases potential opportunities for lumakras drug market participants in the healthcare industry to develop in the near future.
Lumakras Drug Market Report Highlights:
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.
Read Detailed Index of full Research Study @ https://www.absolutemarketsinsights.com/reports/Global-Lumakras-Drug-Market-2021-2029-1089
Browse more trending reports by Absolute Markets Insights:
https://www.absolutemarketsinsights.com/reports/Naloxone-Spray-Market-2019-2027-274
https://www.absolutemarketsinsights.com/reports/Global-Webbing-Market-By-Material-2021---2029-812
About Us:
Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.
Contact Us:
Contact Name: Shreyas Tanna
Company: Absolute Markets Insights
Email Id: sales@absolutemarketsinsights.com
Phone: IN +91-7400-24-24-24, US +1-510-420-1213
Website: www.absolutemarketsinsights.com
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian